Menu

News

InSphero and DefiniGEN Receive Eurostars Grant to Develop Human Stem Cell-derived Screening Platform for Diabetes Drug Discovery

InSphero and DefiniGEN Receive Eurostars Grant to Develop Human Stem Cell-derived Screening Platform for Diabetes Drug Discovery

24th September 2019

InSphero and DefiniGEN Receive Eurostars Grant to Develop Human Stem Cell-derived Screening Platform for Diabetes Drug Discovery New platform to combine stem cell and CRISPR gene-editing technology with proven 3D cell culture techniques for producing standardized pancreatic islet disease models Schlieren, Switzerland and Cambridge, UK– September 24, 2019  InSphero AG and DefiniGEN Ltd. today announced […]

ERS Genomics CRISPR License Agreement | DefiniGEN

ERS Genomics CRISPR License Agreement | DefiniGEN

4th January 2019

DUBLIN, Ireland, and CAMBRIDGE, UK, November 1, 2018 – ERS Genomics Limited and DefiniGEN Ltd announced today a license agreement to provide DefiniGEN with access to ERS Genomic’s CRISPR/Cas9 genome editing technology patents. DefiniGEN will combine their best-in-class iPSC (induced Pluripotent Stem Cell) differentiation platform with CRISPR/Cas9 technology to generate a range of innovative preclinical […]

Attending World Preclinical Congress 2018 | DefiniGEN

Attending World Preclinical Congress 2018 | DefiniGEN

30th November 2018

DefiniGEN will be attending the World Preclinical Congress Europe on November 27-30th 2018 in Lisbon. DefiniGEN invites all WPC 2018 attendees wanting to discover more about how its range of human cell products and services can be used in disease modelling and drug discovery applications to visit booth #18. Contact us to arrange a meeting […]